Strategic Collaboration Exogene has a recent strategic collaboration with Immunocore to engineer T-cell receptors using AI, indicating a potential interest in partnerships that combine AI-driven discovery with partners capable of advancing TCR-based therapies.

AI Platform The company emphasizes a proprietary lab-in-the-loop AI platform for designing multi-specific immune engager drugs, presenting an opportunity to offer AI/ML optimization tools, data services, or computational biology partnerships to accelerate their R&D.

In-House Data Funding to develop core wet-lab datasets for training and validating the AI platform suggests a receptiveness to data generation, annotation, and analytics collaborations, as well as potential needs for data management and cloud-based compute solutions.

TCR Discovery Focused on T-cell receptor discovery and TCR-based cell therapies, Exogene could benefit from early-access pharma/bioindustry collaborations, CRO partnerships, or capability expansions in high-throughput screening, vector design, and GMP-ready production support.

Funding Position With modest revenue and early-stage funding, Exogene may be open to co-development, licensing, or grant-backed programs with larger biotech players seeking to de-risk early AI-enabled TCR programs and entry into immunotherapy pipelines.